To achieve the WHO’s objective to globally eliminate hepatitis B virus (HBV) infection by 2030, it is essential to prevent mother-to-child transmission of HBV. Administration of the hepatitis B vaccine to neonates, preferably within 24 hours after birth, is a key intervention recommended by the WHO to reach this goal. However, the timely administration of hepatitis B birth dose vaccine (HepB-BD) has not been well implemented in low- and middle-income countries for multiple reasons, including a high rate of childbirth at home.
The Special Issue of the Vaccines (impact factor: 4.760) aims to uncover the current situation on the implementation of the HepB-BD, the challenges and facilitators for its timely administration, and potential innovations to overcome these problems. This Special Issue welcomes the submission of papers from a wide range of disciplines including basic science, clinical/epidemiological research, social/anthropological studies, and health economy. The deadline for the manuscript submissions is 31 March 2021.
Dr. Yusuke Shimakawa
Emerging Disease Epidemiology Unit